# Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer

> **NCT02089763** · PHASE2 · COMPLETED · sponsor: **Bio-Cancer Treatment International Limited** · enrollment: 27 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** pegylated recombinant human arginase

## Key facts

- **NCT ID:** NCT02089763
- **Lead sponsor:** Bio-Cancer Treatment International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2021-08-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02089763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02089763, "Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer". Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/clinical/NCT02089763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*